Cited by 200Neuropeptides and Animal PhysiologyNeuroendocrine regulation and behaviorChemical Synthesis and Analysis

The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Griebel, Guy, Holsboer, Florian·2012·Nature Reviews Drug Discovery

Open this paper in CoChat — free account

Abstract

The search for novel drugs for treating psychiatric disorders is driven by the growing medical need to improve on the effectiveness and side-effect profile of currently available therapies. Given the wealth of preclinical data supporting the role of neuropeptides in modulating behaviour, pharmaceutical companies have been attempting to target neuropeptide receptors for over two decades. However, clinical studies with synthetic neuropeptide ligands have been unable to confirm the promise predicted by studies in animal models. Here, we analyse preclinical and clinical results for neuropeptide receptor ligands that have been studied in clinical trials for psychiatric diseases, including agents that target the receptors for tachykinins, corticotropin-releasing factor, vasopressin and neurotensin, and suggest new ways to exploit the full potential of these candidate drugs.

Integrity signals

Registry

Crossref · 10.1038/nrd3702

Cites

176 of 176 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
Self-citation
Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
Characterization of a 41-Residue Ovine Hypothalamic Peptide that Stimulates Secretion of Corticotropin and β-Endorphin
Vale, W., Spiess, J., RIVIER, C. L., & Rivier, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
Stress and Depression
Hammen, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143938 · Cited by 2,979
Causal Relationship Between Stressful Life Events and the Onset of Major Depression
Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.837 · Cited by 2,566
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Self-citation
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
The link between childhood trauma and depression: insights from HPA axis studies in humans
Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704
Peptidergic neurones
Hökfelt, T. G. M., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,552

Flagged first, then by citations

Show all 176 references

Research works printed but not linked: 6

Chappell, P. Effect of CP-122,721, a selective NK-1 receptor antagonist, in patients with MDD. In: Proceedings of the 42nd Annual Meeting of the New Clinical Drug Evaluation Unit (Boca Raton, Florida, 2002).
Ratti, E. et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J. Clin. Psychopharmacol. 31, 727–733 (2011). · DOI
Liebowitz, M., Sheehan, D., Melia, L. A. & Siffert, J. Safety and efficacy of AV608 in subjects with social anxiety disorder. In: Proceedings of the 47th Annual Meeting of the New Clinical Drug Evaluation Unit (Boca Raton, Florida, 2007).
Wernet, W. et al. In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558. Program No. 560.16. 2008 Neuroscience Meeting Planner (Washington DC; Society for Neuroscience; 2008).
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). (American Psychiatric Association, Washington DC, 2000).
Kirsch, I. The Emperor's New Drugs: Exploring the Antidepressant Myth (Bodley Head, 2010).

Sorted by citations

Items 101–200 of 200

Combination therapy with neuropeptides for the treatment of anxiety disorder
Gupta, P. R., & Prabhavalkar, K. S. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102127 · Cited by 17
Antidepressant/anxiolytic potential and adverse effect liabilities of melanin-concentrating hormone receptor 1 antagonists in animal models
Chaki, S., Shimazaki, T., Nishiguchi, M., Funakoshi, T., Iijima, M., Ito, A., Kanuma, K., & Sekiguchi, Y. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.05.018 · Cited by 17
Cardinal role of the environment in stress induced changes across life stages and generations
Pang, T. Y., Yaeger, J. D. W., Summers, C. H., & Mitra, R. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.012 · Cited by 17
Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function
Yu, H., Ni, P., Zhao, L., Tian, Y., Li, M., Li, X., Wei, W., Wei, J., Deng, W., Du, X., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1180720 · Cited by 16
Neuronal circuits of fear memory and fear extinction
Wotjak, C. T., & Pape, H. (2013) · e-Neuroforum · doi:10.1007/s13295-013-0046-0 · Cited by 22
Expression of galanin and its receptors are perturbed in a rodent model of mild, blast-induced traumatic brain injury
Kawa, L., Barde, S. S., Arborelius, U. P., Theodorsson, E., Agoston, D. V., Risling, M., & Hökfelt, T. G. M. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.019 · Cited by 16
IFN ‐α/β‐mediated NK2R expression is related to the malignancy of colon cancer cells
Xiang, H., Toyoshima, Y., Shen, W., Wang, X., Okada, N., Kii, S., Sugiyama, K., Nagato, T., Kobayashi, H., Ikeo, K., et al. (2022) · Cancer Science · doi:10.1111/cas.15397 · Cited by 16
Hypothalamic stress systems in mood disorders
(2021) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-819973-2.00003-4 · Cited by 15
Self-citation
Transient and Stable Expression of the Neurotensin Receptor NTS1: A Comparison of the Baculovirus-Insect Cell and the T-REx-293 Expression Systems
Xiao, S., White, J. F., Betenbaugh, M. J., Grisshammer, R., & Shiloach, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063679 · Cited by 15
The Seven Pillars of Molecular Pharmacology: GPCR Research Honored with Nobel Prize for Chemistry
Hausch, F., & Holsboer, F. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201208565 · Cited by 14
Self-citation
Recurrent major depressive disorder: Imbalance of neurokinin (NK)-1 and NK-2 receptor expression in monocytes
Bardelli, C., Amoruso, A., Manzetti, E., Fresu, L. G., Valsesia, R., Zeppegno, P., & Brunelleschi, S. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.022 · Cited by 14
Asymmetric Synthesis of Merck’s Potent hNK 1 Antagonist and Its Stereoisomers via Tandem Acylation/[3,3]-Rearrangement of 1,2-Oxazine N -Oxides
Dorokhov, V. S., Nelyubina, Y. V., Ioffe, S. L., & Sukhorukov, A. Y. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c01322 · Cited by 14
Vasopressin as Possible Treatment Option in Autism Spectrum Disorder
László, K., Vörös, D., Correia, P., Fazekas, C. L., Török, B., Plangár, I., & Zelena, D. (2023) · Biomedicines · doi:10.3390/biomedicines11102603 · Cited by 13
The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1)
Fruscia, P. D., He, Y., Koenig, M., Tabrizifard, S., Nieto, A., McDonald, P. H., & Kamenecka, T. M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.033 · Cited by 13
A Second Wave for the Neurokinin Tac2 Pathway in Brain Research
Abed, A. S. A., Reynolds, N., & Dehorter, N. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.016 · Cited by 12
Neuropeptides in Psychiatry
Suchak, V., Sathyanath, S., & Kakunje, A. (2022) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_91_22 · Cited by 12
Control of Stress-Induced ACTH Secretion by Vasopressin and CRH: Additional Evidence
Ramos, A. T., Tufik, S., & Troncone, L. R. P. (2016) · Neuropsychobiology · doi:10.1159/000445480 · Cited by 11
NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids
Simeth, N. A., Bause, M., Dobmeier, M., Kling, R. C., Lachmann, D., Hübner, H., Einsiedel, J., Gmeiner, P., & König, B. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.039 · Cited by 11
The neurokinin-3 receptor (NK3R) antagonist SB222200 prevents the apomorphine-evoked surface but not nuclear NK3R redistribution in dopaminergic neurons of the rat ventral tegmental area
Hether, S., Misono, K., & Lessard, A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.05.006 · Cited by 10
Does Stress Elicit Depression? Evidence From Clinical and Preclinical Studies
Sickmann, H. M., Li, Y., Mørk, A., Sánchez, C., & Gulinello, M. E. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_292 · Cited by 10
Vasopressin as a Stress Hormone
Antoni, F. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802175-0.00009-7 · Cited by 13
In Silico Investigation of the Neurotensin Receptor 1 Binding Site: Overlapping Binding Modes for Small Molecule Antagonists and the Endogenous Peptide Agonist
Lückmann, M., Holst, B., Schwartz, T. W., & Frimurer, T. M. (2015) · Molecular Informatics · doi:10.1002/minf.201500080 · Cited by 10
A bipolar disorder-associated missense variant alters adenylyl cyclase 2 activity and promotes mania-like behavior
Sen, P., Ortiz, O., Brivio, E., Menegaz, D., Elliott, L. S., Du, Y., Ries, C., Chen, A., Wurst, W., López, J. P., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02663-w · Cited by 10
Neurotensins and Their Therapeutic Potential: Research Field Study
Yeung, A. W. K., Georgieva, M. G., Kirilov, K., Balacheva, A. A., Peeva, M. I., Horbańczuk, O. K., Horbańczuk, J. O., Lucarini, M., Durazzo, A., Santini, A., et al. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0124 · Cited by 9
Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the Old to the New Paradigm and Assessment of Drug–Transporter Interactions
Reichel, A. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_12 · Cited by 9
Kinetic Profile of Neuropeptide–Receptor Interactions
Nederpelt, I., Bunnik, J., IJzerman, A. P., & Heitman, L. H. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.09.008 · Cited by 9
Olfactory marker protein elevates basal cAMP concentration
Nakashima, N., Nakashima, K., Nakashima, A., & Takano, M. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.087 · Cited by 9
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs
Ferreira, G. S., Dijkstra, F. M., Veening-Griffioen, D. H., Boon, W., Schellekens, H., Moors, E. H. M., van Meer, P. J. K., Stuurman, F. E., & van Gerven, J. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02353-1 · Cited by 8
Exploring the involvement of Tac2 in the mouse hippocampal stress response through gene networking
Hook, M., Xu, F., Terenina, E. E., Zhao, W., Starlard‐Davenport, A., Mormède, P., Jones, B. C., Mulligan, M. K., & Lu, L. (2019) · Gene · doi:10.1016/j.gene.2019.02.013 · Cited by 8
Critical Extracellular Ca2+ Dependence of the Binding between PTH1R and a G-Protein Peptide Revealed by MD Simulations
Li, M., Bao, Y., Xu, R., La, H., & Guo, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00176 · Cited by 8
Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point
Holsboer, F., & Ising, M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2372-3549 · Cited by 8
Self-citation
IFN‐γ–STAT1 ‐mediated NK2R expression is involved in the induction of antitumor effector CD8 + T cells in vivo
Shen, W., Wang, X., Xiang, H., Shichi, S., Nakamoto, H., Kimura, S., Sugiyama, K., Taketomi, A., & Kitamura, H. (2023) · Cancer Science · doi:10.1111/cas.15738 · Cited by 8
The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models
Greek, R. (2014) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2014.516129 · Cited by 10
Psychopharmacologie de l’anxiété et de la dépression : aspects historiques, traitements actuels et perspectives
Javelot, H. (2015) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2015.09.001 · Cited by 8
Bridging animal models and humans: neuroimaging as intermediate phenotypes linking genetic or stress factors to anhedonia
Guo, H., Xiao, Y., Dong, S., Yang, J., Zhao, P., Zhao, T., Cai, A., Tang, L., Liu, J., Wang, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03850-4 · Cited by 7
Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects
Ramos, A. T., Homem, K. S. D. C., Suchecki, D., Tufik, S., & Troncone, L. R. P. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.02.024 · Cited by 8
Plasma neuropeptides as circulating biomarkers of multifactorial schizophrenia
Ni, P., Tian, Y., Gu, X., Yang, L., Wei, J., Wang, Y., Zhao, L., Zhang, Y., Zhang, C., Li, L., et al. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.152114 · Cited by 7
Activation Pathways of Neurotensin Receptor 1 Elucidated Using Statistical Machine Learning
Yadav, P., & Farimani, A. B. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00154 · Cited by 7
Genetic Rat Models for Schizophrenia
Ellenbroek, B. A., & Karl, T. (2015) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00018-3 · Cited by 8
Understanding the Allosteric Modulation of PTH1R by a Negative Allosteric Modulator
Li, M., Bao, Y., Xu, R., Li, M., Xi, L., & Guo, J. (2022) · Cells · doi:10.3390/cells12010041 · Cited by 6
Generalized Anxiety Disorder: A Review of Current Literature in Saudi Arabia
Bamalan, O. A., Alosaimi, N. M., Alfryyan, A. A., Aljubran, H. J., Alanazi, F. H., & Siddiqui, Z. I. (2023) · Psychology · doi:10.4236/psych.2023.141003 · Cited by 6
Cross-species analysis uncovers the mitochondrial stress response in the hippocampus as a shared mechanism in mouse early life stress and human depression
Hofstra, B., Hoeksema, E. E., Kas, M. J., & Verbeek, D. S. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100643 · Cited by 7
Genetic-epigenetic-neuropeptide associations in mood and anxiety disorders: Toward personalized medicine
Gilani, M., Abak, N., & Saberian, M. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173897 · Cited by 6
Melanin-concentrating hormone: A promising target for antidepressant treatment
Shi, L., He, Y., Lian, Y., Luo, J., Zhu, X., & Zhao, H. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.173999 · Cited by 6
Melanin-concentrating hormone receptor: A therapeutic target for novel anxiolytics
Chaki, S. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173818 · Cited by 6
Die sieben Säulen der molekularen Pharmakologie: GPCR‐Forschung mit Chemie‐Nobelpreis geehrt
Hausch, F., & Holsboer, F. (2012) · Angewandte Chemie · doi:10.1002/ange.201208565 · Cited by 6
Self-citation
Environmental manipulations generate bidirectional shifts in both behavior and gene regulation in a crossbred mouse model of extremes in trait anxiety
Chekmareva, N. Y., Sotnikov, S., Diepold, R., Naik, R., Landgraf, R., & Czibere, L. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00087 · Cited by 6
Pharmacogenomics of Neuropsychiatric Disorders: Analysis of Genetic Variability in 162 Identified Neuroreceptors using 1000 Genomes Project Data
Kaur, H., Jajodia, A., Grover, S., Agarwal, N., Baghel, R., & Kukreti, R. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.113 · Cited by 5
A New Paradigm Shift in Antidepressant Therapy: From Dual-action to Multitarget-directed Ligands
Rodríguez-Lavado, J., Alarcón‐Espósito, J., Mallea, M., & Lorente, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220317121551 · Cited by 5
MCH Receptor 1 Antagonists: Antidepressant/Anxiolytic Potential in Animal Models
Chaki, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-75765-0_12 · Cited by 4
Comparative Perspectives on Neuropeptide Function and Social Isolation
Asahina, K., & Zelikowsky, M. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.01.019 · Cited by 4
Snapshot of an activated peptide receptor
Hausch, F., & Holsboer, F. (2012) · Nature · doi:10.1038/nature11634 · Cited by 4
Self-citation
Corticotropin-Releasing Hormone in the Paraventricular Nucleus of the Hypothalamus—Beyond Hypothalamic–Pituitary–Adrenal Axis Control
Chang, S., & Deussing, J. M. (2021) · Masterclass in neuroendocrinology · doi:10.1007/978-3-030-86630-3_9 · Cited by 4
Protein-protein interactions at a glance: Protocols for the visualization of biomolecular interactions
Agamennone, M., Nicoli, A., Bayer, S., Weber, V., Borro, L., Gupta, S. K., Fantacuzzi, M., & Pizio, A. D. (2021) · Methods in cell biology · doi:10.1016/bs.mcb.2021.06.012 · Cited by 4
The Current Status of Drug Discovery for the Oxytocin Receptor
Nashar, P. E., Whitfield, A. A., Mikušek, J., & Reekie, T. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1759-5_10 · Cited by 4
Epigenetics and Neuroendocrinology
Binder, E. B., & Spengler, D. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-29901-3 · Cited by 4
Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia
Sun, W., Jin, T., Yang, H., Li, J., Tian, Q., Gao, J., Peng, R., Zhang, G., & Zhang, X. (2024) · Schizophrenia · doi:10.1038/s41537-023-00425-1 · Cited by 3
Neuroproteomics: Unveiling the Molecular Insights of Psychiatric Disorders with a Focus on Anxiety Disorder and Depression
Rodrigues‐Ribeiro, L., Resende, B. L., Dias, M. L. P., Lopes, M. R., de Barros, L. L. M., Moraes, M. A., Verano‐Braga, T., & Souza, B. R. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-50624-6_6 · Cited by 3
Current Approaches to the Search of Anxiolytic Drugs
Maltsev, D. V., Спасов, А. А., Мирошников, М. В., & Skripka, M. O. (2021) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162021030122 · Cited by 3
Non-peptide ligands in the characterization of peptide receptors at the interface between neuroendocrine and mental diseases
Pissarek, M., & Disko, U. (2013) · World Journal of Neuroscience · doi:10.4236/wjns.2013.32014 · Cited by 3
The role of neurotensin in vulnerability for self‐injurious behaviour: studies in a rodent model
Muehlmann, A. M., Wolfman, S. L., & Devine, D. P. (2018) · Journal of Intellectual Disability Research · doi:10.1111/jir.12519 · Cited by 3
Neurotensin counteracts hair growth inhibition induced by chronic restraint stress
Chen, L., Yu, Q., Guo, F., Wang, X., Cai, Z., & Zhou, Q. (2023) · Experimental Dermatology · doi:10.1111/exd.14990 · Cited by 2
Development of a Genetic Test Indicating Increased AVP/V1b Signalling in Patients with Acute Depression
Ising, M., Holsboer, F., Myhsok, M., & Müller‐Myhsok, B. (2025) · Pharmacopsychiatry · doi:10.1055/a-2508-5834 · Cited by 2
Self-citation
Novel Targets for Drug Treatment in Psychiatry
Kurita, M., García‐Bea, A., & González‐Maeso, J. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_30 · Cited by 1
Role of the medial septum neurotensin receptor 1 in anxiety-like behaviors evoked by emotional stress
Chang, L., He, Y., & Li, B. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107275 · Cited by 1
Social Neuropeptides and Behavior
Piper, W. T., & Saturn, S. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397045-9.00046-x · Cited by 1
Kisspeptin modulates the activity of the stress system and associated behaviours, the body temperature and nociception
Csabafi, K. (2014) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.2475 · Cited by 1
Neuropeptides in mental health: CRF, AVP, and OXT
Hammock, E. A. D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91497-0.00211-3 · Cited by 1
Mood and Anxiety Disorders
Griebel, G., & Beeské, S. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679348.ch09
Self-citation
Neuropeptides: Active Neuromodulators Involved in the Pathophysiology of Suicidal Behavior and Major Affective Disorders
Serafini, G., Lindqvist, D., Brundin, L., Dwivedi, Y., Girardi, P., & Amore, M. (2014) · Wiley eBooks · doi:10.1002/9783527684403.ch15
Anxiety and mood disorders
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.021
Future perspectives on the pharmacological management of depression
Yates, S., Smith, E., Alhaj, H. A., & McAllister-Williams, H. (2013) · Clinical Investigation · doi:10.4155/cli.12.152
Modelling Stress‐Related Mood Disorders in Animals
Schmidt, M. V., Wagner, K. V., Wang, X., & Balsevich, G. (2015) · Wiley eBooks · doi:10.1002/9781118921692.ch8
Neuropeptides in Mental Health: CRF, AVP, and OXT
Hammock, E. A. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397045-9.00137-3
Interações moleculares no mecanismo de ação da galectina-4 humana
Kumagai, P. S. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2016.tde-14062016-143750
Antiamnesic properties of analogs and mimetics of the tripeptide human urocortin 3
Telegdy, G., Kovács, A. K., Rákosi, K., Zarándi, M., & Tóth, G. K. (2016) · Amino Acids · doi:10.1007/s00726-016-2268-2
Corticotropin-Releasing Factor and Urocortin Receptors
Grigoriadis, D. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802175-0.00006-1
Antidepressant Therapy for Depression: An Update
Gupta, D., & Mahesh, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_17
Tachykinins
Turiault, M., Cohen, C., & Griebel, G. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_210
Self-citation
Tachykinins
Turiault, M., Cohen, C., & Griebel, G. (2014) · Springer eBooks · doi:10.1007/978-3-642-27772-6_210-2
Self-citation
Novel Approaches for Treating Anxiety Disorders
Sturman, D. A., Kaufman, M. L., Bigony, C. E., & Ressler, K. J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0039
Faculty Opinions recommendation of β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.
Shukla, A. K. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738029959.793575371
Cross-species neuroimaging intermediate phenotypes deepen our understanding of depressionPreprint
Guo, H., Dong, S., Xiao, Y., Yang, J., Zhao, P., Zhao, T., Cai, A., Wang, H., Hua, R., Liu, R., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2414671/v1
Cross-species neuroimaging intermediate phenotypes deepen our understanding of depressionPreprint
Guo, H., Dong, S., Xiao, Y., Yang, J., Zhao, P., Zhao, T., Cai, A., Wang, H., Hua, R., Liu, R., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2414671/v2
Patologia biochimică a substanţei P în neuropsihiatrie
Istrate, B. M. (2023) · Psihiatru ro · doi:10.26416/psih.72.1.2023.7933
Preclinical evaluation of thymol in alcohol withdrawal-induced behavioral and motor deficits in mice
Jadhav, S., Mahajan, M., Upaganlawar, A., & Upasani, C. (2025) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2025.23.1.0659
Chronic psychosocial stress-induced pathologies in male C57BL/6 mice - impact of the central oxytocinergic system
Peters, S. (2014) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.29943
Synthèse de nouveaux conjugués fluorocarbonés pour augmenter la stabilité métabolique de peptides thérapeutiques ciblant les récepteurs couplés aux protéines G : application aux peptides apeline et spexine, étude mécanistique et évaluation biologique.
Ramanoudjame, S. M. (2020) · theses.fr (ABES) · doi:10.70675/9aaefdefz6dafz4974za324zc779e3d0df04
Study of the therapeutic potentials of the induced augmentation in adult neurogenesis in a mouse model of chronic mild stress and depression
Eliwa, H. (2020) · theses.fr (ABES) · doi:10.70675/d246defdz6649z4d6fza1f9z50300ef2d10d
Vasopressin 1a Receptor Antagonists for Pathological Aggression in Neurodegenerative and Other CNS Diseases
Simon, N. G., Brownstein, M., Anderson, K. E., Lu, S., & Maibach, H. T. (2026) · Biomedicines · doi:10.3390/biomedicines14040889
Communication in the Depressed Brain
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_7
Comparison of copeptin levels in manic episode and remission periods in patients with bipolar disorder and its relationship with sleep, circadian rhythm and functionality
İlter, İ., Ceyhun, H. A., & Öztürk, N. (2026) · Biological Rhythm Research · doi:10.1080/09291016.2026.2678268
Docking of virtual libraries identifies small-molecule agonists of neurotensin receptors with analgesic activity
Panel, N., Vo, D. D., Hübner, H., Deluigi, M., Pach, S., Bélair, F., Weikert, D., Klenk, C., Hilge, M., Shiva, N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74990-1
Peptide-protein interactions in drug discovery
Ying, H., Lei, Y., Luo, Y., Zeng, J., & de la Fuente‐Núñez, C. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100598
BindingDB Entry 50043411: TBA
BindingDB (2014) · UC San Diego · doi:10.7270/q2959jzq
BindingDB Entry 50008421: Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.
BindingDB (2021) · UC San Diego · doi:10.7270/q2hq438v
BindingDB Entry 50045190: The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1).
BindingDB (2016) · UC San Diego · doi:10.7270/q2zp47rg
BindingDB Entry 50048156: NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids.
BindingDB (2018) · UC San Diego · doi:10.7270/q2dr2xg4
BindingDB Entry 7803: Ligand Discovery for a Peptide-Binding GPCR by Structure-Based Screening of Fragment- and Lead-Like Chemical Libraries.
BindingDB (2017) · UC San Diego · doi:10.7270/q2542mfk
BindingDB Entry 50001633: Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A-E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium.
BindingDB (2020) · UC San Diego · doi:10.7270/q2n87d9x

Authors: Griebel, G., & Holsboer, F.
Affiliations: Sanofi (France) (FR)
Max Planck Institute of Psychiatry (DE)
Corresponding author: Griebel, Guy
ORCID: Griebel, Guy
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2012-05-18
Volume: 11
Issue: 6
Pages: 462-478
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd3702
OpenAlex: W2089617519
Cited by: 194
References: 176
Citations by year: 2026: 5 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 14 · 2020: 9 · 2019: 10 · 2018: 16 · 2017: 13 · 2016: 20 · 2015: 22 · 2014: 19 · 2013: 23 · 2012: 9
FWCI: 2.50
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords: psychiatric drug development, tachykinins, corticotropin-releasing factor, vasopressin, neurotensin, clinical translation, adverse effects
MeSH terms: Animals, Mental Disorders, Corticotropin-Releasing Hormone, Humans, Ligands, Neurotensin, Psychotropic Drugs, Vasopressins, Tachykinins, Drug Delivery Systems, Receptors, Vasopressin, Receptors, Neuropeptide, Receptors, Corticotropin-Releasing Hormone, Receptors, Neurotensin, Receptors, Tachykinin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks